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Abstract 
Background 
The clinical effects of varying pharmacokinetic exposures of antibiotics (antibacterials and 
antifungals) on outcome in infected critically ill patients are poorly described. A large-scale 
multi-centre study (DALI Study) is currently underway describing the clinical outcomes of 
patients achieving pre-defined antibiotic exposures. This report describes the protocol. 
Methods 
DALI will recruit over 500 patients administered a wide range of either beta-lactam or 
glycopeptide antibiotics or triazole or echinocandin antifungals in a pharmacokinetic point-
prevalence study. It is anticipated that over 70 European intensive care units (ICUs) will 
participate. The primary aim will be to determine whether contemporary antibiotic dosing for 
critically ill patients achieves plasma concentrations associated with maximal activity. 
Secondary aims will compare antibiotic pharmacokinetic exposures with patient outcome and 
will describe the population pharmacokinetics of the antibiotics included. Various subgroup 
analyses will be conducted to determine patient groups that may be at risk of very low or very 
high concentrations of antibiotics. 
Discussion  
The DALI study should inform clinicians of the potential clinical advantages of achieving 
certain antibiotic pharmacokinetic exposures in infected critically ill patients. 
Keywords 
Antibiotic, βeta-lactam, Glycopeptide, Triazole, Echinocandin, Continuous infusion, 
Extended infusion, Bolus dosing, Adverse events, Pharmacokinetics, Pharmacodynamics 
Background 
Effective antibiotic treatment of intensive care unit (ICU) patients that have overwhelming 
infections, including sepsis, severe sepsis and septic shock, remains a significant challenge to 
physicians world-wide [1-7]. Therapy that is not initiated rapidly or with sufficient antibiotic 
spectrum increases in-hospital mortality [3,4]. Indeed, sepsis itself has an incidence in the 
population that exceeds colon cancer, breast cancer, and AIDS, with mortality rates of 30% 
for mild to moderate sepsis and up to 82% for severe sepsis and septic shock [5]. Despite 
advances in critical care medicine, the incidence of sepsis continues to increase and the 
prognosis remains poor. Although there has been significant investment into treatments that 
limit the various inflammatory and coagulation cascades, none of these therapies have been 
able to demonstrate the same outcome benefits as effective antibiotic therapy [3,8]. It is 
thought that optimisation of antibiotic dosing may well further improve clinical outcomes for 
ICU patients with infections. 
Drug doses are usually derived from healthy volunteers and then extrapolated into ICU 
patients. A challenge for clinicians is that standard dosing in ICU patients does not achieve 
the same concentrations seen in non-critically ill patients [9]. There is a significant body of 
literature that demonstrates that disease-processes experienced by critically ill patients 
frequently cause pharmacokinetic changes that may result in either sub-therapeutic or toxic 
drug concentrations of antibiotics (including antibacterial and antifungal drugs) [9-17]. Given 
the increased level of resistance of bacteria in the ICU [18], and these potentially lower 
antibiotic exposures, treatment failure of infections is unsurprisingly common. 
Subtherapeutic drug levels may also promote selection of resistant microorganisms, further 
adding to the threat of antimicrobial resistance in the ICU. To address this issue innovative 
approaches to dosing may be required to ensure optimal drug exposures [19-21]. 
Although altered antibiotic concentrations have been accurately described in various critically 
ill patient sub-populations in small research studies [21-28], there is no large multi-centre 
evaluation that seeks to determine whether the issues identified in a controlled research 
environment correspond to clinical practice. Such an evaluation is essential for determining 
whether action is required to change existing global antibiotic prescribing practices for 
critically ill patients. If prescribing should be found to be sub-optimal, then the motivation for 
changes to existing prescribing practice may lead to improved clinical cure rates and a 
reduction in the rate of antibiotic resistance in the critical care environment. To address the 
insufficiency of data available to clinicians on the adequacy of empiric antibiotic dosing in 
ICU patients, on behalf of the Infection Section of the European Society of Intensive Care 
Medicine, the authors proposed a multicentre point-prevalence pharmacokinetic study in ICU 
patients. 
This proposal has been supported by the European Society of Intensive Care Medicine’s 
European Critical Care Research Network (ESICM ECCRN) and Trials Group and also the 
Royal Brisbane and Women’s Hospital Research Foundation (Australia). This report 
describes the study protocol. 
Based on our previous research in many different critically ill patient sub-populations, we 
hypothesize that 40 to 70% of critically ill patients are receiving suboptimal antibiotic dosing 
[23,27-33]. 
Methods/Design 
The Defining Antibiotic Levels in Intensive care unit patients (DALI) study is a prospective, 
multi-centre pharmacokinetic point-prevalence study describing whether contemporary 
antibiotic dosing in ICU patients achieves concentrations associated with maximal activity. It 
is anticipated that the study will recruit over 500 ICU patients from over 70 ICUs throughout 
9 countries in Europe over a one-week period. The primary and secondary aims as well as the 
proposed sub-group analyses are as follows: 
Primary Aim  
 To determine whether contemporary antibiotic dosing for critically ill patients 
achieves concentrations associated with maximal activity. 
Secondary Aims 
 Comparison of observed antibiotic pharmacokinetics/pharmacodynamics with the 
clinical outcome of therapy 
 Description of the population pharmacokinetics of the individual antibiotics in ICU 
patients 
The proposed subgroups for the primary and secondary aims are: 
 Patients administered intermittent dosing versus extended or continuous infusions and  
 Patients with ‘steady-state’ versus ‘non-steady-state’ pharmacokinetics (‘non-steady-
state’ defined as antibiotics commenced within 24-h prior to sampling) 
 Patients with different levels of sickness severity as measured by Sequential Organ 
Failure Assessment (SOFA) Score[34], Acute Physiology and Chronic Health 
Evaluation (APACHE) II Score[35] and PIRO (Predisposition, Infection, Response, 
Organ dysfunction) Score[36] 
 Different admission diagnoses 
 Different indications for antibiotic therapy 
 Presence of surgery within the 24-hours prior to sampling 
 Different total body weight 
 Different levels of renal function and presence of extracorporeal renal support 
techniques 
Participants 
Identification of eligible patients will occur on a designated day (preferably Monday) of a 
nominated week. Informed consent is required from each patient or a legally authorised 
representative to participate in the study.Participants would need to fulfil all the inclusion and 
exclusion criteria to be enrolled:  
Inclusion criteria 
• Written informed consent has been obtained from the patient or their legally 
authorised representative 
• Age ≥ 18 years 
• Receiving antibiotic therapy of one of the target drugs via continuous or intermittent 
dosing regimen 
• Suitable intravenous/intra-arterial access to facilitate sample collection 
 
Exclusion criteria 
• Consent not obtained 
• Aged < 18 years of age 
• Not being administered any of the study antibiotics 
• Limited or no intravenous/intra-arterial access. 
 
Study treatments and pharmacokinetic sampling 
With the exception of blood sampling, there is no intervention in this study that may affect 
patient treatment. Antibiotic dosing will occur as deemed by the treating clinician and their 
local dosing practices. Patients receiving the study antibiotics will be identified on the 
nominated week for pharmacokinetic sampling. During a single dosing interval of that week, 
each patient will then have two blood samples taken for each antibacterial agent and/or three 
blood samples for antifungals (Table 1). For patients on multiple study drugs, each drug will 
be sampled independent of the other drug(s). Table 1 outlines the test antibiotics 
(antibacterials and antifungals) to be sampled, the timing of pharmacokinetic sampling and 
the pharmacodynamics endpoints that will be tested for each antibiotic and dosing regimen. 
Table 1 Study drugs, routes of administration, pharmacokinetic/pharmacodynamic 
targets and blood sampling 
Study Drugs and method of infusion Pharmacokinetic 
Sampling 
Pharmacodynamic 
Targets tested 
Beta-lactam antibiotics by intermittent 
infusion 
Sample A: mid-way 
through dosing interval 
(50% of dosing interval) 
• 50% f T>MIC 
(amoxycillin-clavulanate; ampicillin; 
piperacillin-tazobactam; penicillin-G; 
flucloxacillin; dicloxacillin; cloxacillin; 
cephazolin; ceftazidime; ceftriaxone; 
cefepime; meropenem; imipenem; 
doripenem; ertapenem) 
Sample B: within 30 min 
of next dose (100% of 
dosing interval) 
• 50% f T>4xMIC* 
Glycopeptide antibiotics by intermittent 
infusion (vancomycin, teicoplanin) 
• 100% f T>MIC 
• 100% f T>4xMIC 
• 100% f T>4xMIC 
• Concentration ≥15 
mg/L* 
Triazole antifungals (fluconazole, 
voriconazole) 
Sample A: 30 min after 
completion of intravenous 
infusion (peak 
concentration) 
• AUC0-24/MIC 
≥25* 
Echinocandin antifungals (caspofungin, 
micafungin, anidulafungin) 
Sample B: mid-way 
through dosing interval 
(50% of dosing interval) 
• AUC0-24/MIC 
≥20* 
Sample C: within 30 min 
of next dose (100% of 
dosing interval) 
Beta-lactam antibiotics (listed above) by 
continuous infusion 
Sample A: at any time • 100% f T>4xMIC* 
Sample B: >6 hours after 
sample A Glycopeptide antibiotics (listed above) by 
continuous infusion 
• 100% f T>4xMIC* 
• AUC0-24/MIC 
≥350 
* denotes the primary endpoint – other stated pharmacodynamics targets are secondary 
endpoints. 
f T>MIC is the duration of a dosing interval for which the antibiotic concentration remains 
above the minimum inhibitory concentration (MIC) of the known or suspected pathogen 
(endpoints of 50% or 100% of the interval, and MIC is defined by EUCAST MIC90 data); f 
T>4xMIC is the duration of a dosing interval for which the antibiotic concentration remains 
above a concentration that is 4 x the MIC of the known or suspected pathogen (endpoints of 
50% or 100% of the interval, and MIC is defined by EUCAST MIC90 data); AUC0-24/MIC is 
the ratio of the area under the concentration time curve from 0–24 hours to MIC. 
The blood sampling has been designed to determine drug concentrations at various time 
points to describe whether pharmacokinetic/pharmacodynamic targets are achieved in 
individual patients (Table 1). To achieve the endpoint 50% f T>MIC, sample A is taken mid-
way through the dosing interval to see if the drug concentration exceeds the MIC. The 100% f 
T>MIC endpoint is similarly assessed from the sample B taken at the end of the dosing interval. 
The endpoint 100% f T>4xMIC, is attained if all sample concentrations exceed the MIC by at 
least a factor of four. For the parameter AUC0-24/MIC, the Area Under the concentration-time 
Curve from 0–24 h (AUC0-24) is calculated by the trapezoidal rule, and to attain the stated 
endpoint, the AUC0-24 must exceed the MIC by the factor listed in Table 1. In all cases the 
MIC of the infective pathogen is defined by The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) MIC90 data; available at: 
http://www.eucast.org/clinical_breakpoints). 
Data collection and management 
Data collection will be conducted by trained staff at each participating centre and entered 
onto a case report form (CRF). At the end of the patient’s participation, the CRF will be sent 
to the coordinating centre (The University of Queensland, Australia). Outstanding queries 
regarding the completion of the CRF will be undertaken with each participating centre where 
necessary to ensure accuracy of data. 
The data to be collected includes.  
Demographic data 
 Age 
 Gender 
 Height 
 Weight 
Clinical data 
 Admission diagnosis, 
 Sickness severity scores (APACHE II, SOFA, PIRO) 
 Presence of extracorporeal circuits (e.g. RRT (renal replacement therapy), ECMO 
(extracorporeal membrane oxygenation)) 
 Procalcitonin (where available), 
 Presence/absence of surgery within previous 24 hours 
 Clinical outcome of infection 
 Mortality at 30-days 
Organ function data 
 Renal function – serum creatinine concentration during studied dosing interval; 
MDRD (modified diet in renal disease) equation 
 8-hours urinary creatinine clearance (where available) 
 Fluid balance for total length of stay and previous 24-hours 
Antibiotic dosing data 
 Dose and frequency 
 Time of dosing and sampling 
 Day of antibiotic therapy 
Infection data 
 Known or presumed pathogen 
 Known or likely minimum inhibitory concentration  (MIC) 
The definitions used to assess clinical outcome of therapy are as follows. A positive clinical 
outcome of therapy is defined as completion of treatment course without change or addition 
of antibiotic therapy, and with no additional antibiotics commenced with 48 h of 
discontinuation of the antibiotic therapy. 
De-escalation is defined as the change to a narrower spectrum antibiotic based on patient-
specific microbiological data in the absence of clinical failure. For antibiotics that are ceased 
before the end of treatment of an infection because of antibiotic de-escalation, these 
antibiotics will be excluded from the a priori analysis. Where de-escalation occurs during the 
target week of sampling, an option for a second sampling period of the new antibiotic will 
exist to confirm appropriateness of antibiotic concentrations and compare these with the 
patient’s clinical outcome. 
Safety data will be collected to define any adverse drug reaction (clinically observed, 
haematological or biochemical) that is reported by the clinical staff at the participating ICUs 
that is suspected as being caused by any of the study antibiotics. 
Maintenance of blood sample integrity 
Blood samples will be kept on ice, centrifuged at 3000 rpm for 10-min, within 6 h of 
collection and the plasma transferred to a labelled cryo-vial for frozen storage (at −20°C or 
lower for short term storage). A commercial courier company specialising in transport of 
clinical samples on dry ice will collect the samples from each site and deliver to the Burns 
Trauma and Critical Care Research Centre at The University of Queensland, Australia for 
bioanalysis. Samples will be stored at −80°C until assay. 
Bioanalysis 
The concentration of the study antibiotics in the biological samples will be determined by 
chromatographic methods (HPLC and LC-MS/MS) that are validated and conducted in 
accordance with the US Food and Drug Administration’s guidance for industry on 
bioanalysis (available at: 
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC
M070107.pdf). 
Ethical issues 
Each of the participating centres has obtained local ethics approvals to conduct the study as 
described in Additional File 1. The University of Queensland is the head institution with 
ethical approval granted by the Medical Research Ethics Committee (201100283 12th April 
2011 and Amendment 201100283 25th May 2011). Patients may withdraw from the study at 
any time without prejudice, as documented and explained at the time of consenting. 
Statistical and pharmacokinetic analysis 
The achievement of the pharmacodynamics targets will be performed by visual inspection of 
the results and comparison with the target. Statistical analyses to test the study objectives will 
be performed using Mann–Whitney U tests or Students t-tests where appropriate using the 
statistical package, SPSS (version 17.0, Illinois, USA). 
The % f T>MIC will be determined using the equation [37]: 
MIC d% ln Dose MIC 1 100 DIelfT V k  
where Vd is volume of distribution calculated as Dose/AUC; MIC is the known or suspected 
minimum inhibitory concentration; kel is the elimination rate constant calculated from the 
gradient of the concentration-time curve in the elimination phase (sample A and sample B) 
and DI is the dosing interval (h). Where infections are polymicrobial, the MIC of the least 
susceptible pathogen will be used in the analysis. 
The population pharmacokinetic parameters of each antibiotic will be determined using a 
population pharmacokinetic modelling approach using NONMEM® (Version 6.1, GloboMax 
LLC, Hanover, MD, USA) as previously described[22,23,25,29,32,38]. Additionally, the 
pharmacokinetic model will aim to determine if significant correlations exist between 
demographic and clinical factors on pharmacokinetics. If one or more of the variables are 
found to have a significant effect on the pharmacokinetics of the drug, then it can be 
incorporated into the final pharmacokinetic model. 
Sample size and power 
Whilst it is not possible to predict the number of patients receiving each of the study 
antibiotics, all data will be useful and can be used to inform clinical practice. It is likely that 
at least 5 of the study antibiotics will have a minimum of 30 patients included in the analysis. 
This sample size will provide a power of 80% (assuming an α of 0.05 and r2 of 30%) for 
defining at least 2–4 covariates predictive of achieving the primary pharmacodynamic 
outcome [39]. For all other included study antibiotics, we estimate that each will have a 
minimum of 12 patients that can be used for the secondary objectives of population 
pharmacokinetic analysis. A minimum of 12 patients per antibiotic is based on data from 
previous non-interventional pharmacokinetic studies in critically ill patients [22,23,32,40]. 
Funding 
This project has received funding from the European Society of Intensive Care Medicine’s 
European Critical Care Research Network (ESICM ECCRN), and the Royal Brisbane and 
Women’s Hospital Foundation. Dr Roberts is funded by a Training Research Fellowship 
from the National Health and Medical Research Council of Australia (569917). 
Discussion 
ICU patients are greatly different in many ways to non-critically ill patients. Principal 
differences relate to the level of sickness severity, the number of therapeutic interventions 
used, the severe pathophysiological changes that occur and the presence of highly resistant 
bacteria and fungi. For these reasons, it unsurprising that ICU patients have poor outcomes 
associated with infections. Whilst early and appropriate treatment of infections significantly 
reduces patient mortality, the additional benefits of optimised antibiotic pharmacokinetic 
exposures have been poorly quantified. ICU pharmacokinetic studies have traditionally only 
enrolled small patient numbers, which greatly limits the ability to describe the significant 
interpatient pharmacokinetic variability that is present, and what effect this may have on 
clinical efficacy. Using a multinational approach to enrol large patients numbers on a wide 
range of commonly used antibiotics, including both antibacterials and antifungals, the DALI 
study will address these knowledge gaps. 
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